VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH CML 2022 | The impact of BCR-ABL mutations on signaling pathway activation in CML

Toshio Kitamura, MD, PhD, The University of Tokyo, Tokyo, Japan, outlines signaling pathways that play a role in the development of chronic myeloid leukemia (CML), discussing the impact of BCR-ABL mutations in the activation of these pathways. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Advisor for Rigel

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter